982 related articles for article (PubMed ID: 24631886)
1. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
2. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156 Suppl 1():3-23. PubMed ID: 26039413
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Dec; 156 Suppl 2():3-24. PubMed ID: 26667111
[TBL] [Abstract][Full Text] [Related]
5. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
[TBL] [Abstract][Full Text] [Related]
6. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2018 Feb; 159(Suppl 1):3-23. PubMed ID: 29478339
[TBL] [Abstract][Full Text] [Related]
7. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
Hunyady B; Abonyi M; Csefkó K; Gervain J; Haragh A; Horváth G; Jancsik V; Makkai E; Müller Z; Ribiczey P; Sipos B; Szabó O; Szalay F; Szentgyörgyi L; Tornai I; Újhelyi E; Varga M; Weisz G; Makara M
Orv Hetil; 2016 Aug; 157(34):1366-74. PubMed ID: 27546804
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
[TBL] [Abstract][Full Text] [Related]
10. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
12. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
[TBL] [Abstract][Full Text] [Related]
13. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
14. [What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?].
Tusnádi A; Szabó A
Orv Hetil; 2013 Feb; 154(7):257-61. PubMed ID: 23395789
[TBL] [Abstract][Full Text] [Related]
15. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
16. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
17. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 15 October 2016].
Horváth G; Gerlei Z; Gervain J; Lengyel G; Makara M; Pár A; Rókusz L; Szalay F; Tornai I; Werling K; Hunyady B
Orv Hetil; 2017 Feb; 158(Suppl 1):23-35. PubMed ID: 28218868
[TBL] [Abstract][Full Text] [Related]
19. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
20. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]